Extradigestive manifestations of IBD in pediatrics

European Review for Medical and Pharmacological Sciences

Volumn 13, Issue SUPPL. 1, 2009, Pages 23-32

  Aloi, Marina ^a   Cucchiara, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Extradigestive manifestations IBD; IBD; Pediatrics IBD

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BEZAFIBRATE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DAPSONE; GROWTH HORMONE; HLA B27 ANTIGEN; HLA B35 ANTIGEN; HLA B44 ANTIGEN; HLA DR ANTIGEN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOXIFYLLINE; SALAZOSULFAPYRIDINE; SOMATOMEDIN C; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE PANCREATITIS; ANEMIA; ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTHROPATHY; BONE MARROW SUPPRESSION; CROHN DISEASE; DRUG WITHDRAWAL; ENTERITIS; EPISCLERITIS; ERYTHEMA NODOSUM; GENETIC PREDISPOSITION; GLAUCOMA; GLOMERULONEPHRITIS; GROWTH DISORDER; HUMAN; INTRAOCULAR PRESSURE; KIDNEY AMYLOIDOSIS; LIVER TRANSPLANTATION; LUNG DISEASE; MOUTH ULCER; NEPHROLITHIASIS; NEUROLOGIC DISEASE; OBSTRUCTIVE UROPATHY; OPTIC NEURITIS; OSTEOPENIA; OSTEOPOROSIS; PERCEPTION DEAFNESS; PERICARDITIS; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PYODERMA GANGRENOSUM; REVIEW; SACROILIITIS; SCLERITIS; SCLEROSING CHOLANGITIS; SIDE EFFECT; THROMBOEMBOLISM; ULCERATIVE COLITIS; URINARY TRACT FISTULA; UVEITIS;

ADOLESCENT; BONE DISEASES, METABOLIC; CHILD; CHOLANGITIS, SCLEROSING; EYE DISEASES; GROWTH DISORDERS; HUMANS; INFLAMMATORY BOWEL DISEASES; MUSCULOSKELETAL DISEASES; SKIN DISEASES; UROLOGIC DISEASES;

EID: 65249138746     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. BERNSTEIN CN, BLANCHARD JF, RAWSTHORNE P, YU N. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am J Gastroenterol 2001; 96: 1116-1122.
2. JUILLERAT P, MOTTET C, FROEHLICH F, FELLEY C, VADER JP, BURNAND B, GONVERS JJ, MICHETTI P. Extraintestinal manifestations of Crohn's disease. Digestion 2005; 71: 31-36.
3. JOSE FA, HEYMAN MB. Extraintestinal manifestations of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2008; 46: 124-133.
4. MENDOZA JL, LANA R, TAXONERA C, ALBA C, IZQUIERDO S, DÍAZ-RUBIO M. Extraintestinal manifestations in inflammatory bowel disease: Differences between Crohn's disease and ulcerative colitis. Med Clin 2005; 125: 297-300.
5. STAWARSKI A, IWANCZAK B, KRZESIEK E, IWANCZAK F. Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease. Pol Merkur Lekarski 2006; 20: 22-25.
6. RATH HC, HERFARTH HH, IKEDA JS, GRENTHER WB, HAMM TE JR, BALISH E, TAUROG JD, HAMMER RE, WILSON KH, SARTOR RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953.
7. ROUSSOMOUSTAKAKI M, SATSANGI J, WELSH K, LOUIS E, FANNING G, TARGAN S, LANDERS C, JEWELL DP. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997; 112: 1845-1853.
8. ORCHARD TR, CHUA CN, AHMAD T, CHENG H, WELSH KI, JEWELL DP. Uveitis and erythema nodosum in inflammatory bowel disease: Clinical features and the role of HLA genes. Gastroenterology 2002; 123: 714-718.
9. BOOT AM, BOUQUET J, KRENNING EP, DE MUINCK KEIZER-SCHRAMA SM. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998; 42: 188-194.
10. BERNSTEIN CN, WAJDA A, BLANCHARD JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study. Gastroenterology 2005; 129: 827-836.
11. PASSO MH, FITZGERALD JF, BRANDT KD. Arthritis associated with inflammatory bowel disease in children. Relationship of joint disease to activity and severity of bowel lesion. Dig Dis Sci 1986; 31: 492-497.
12. GROSSMAN BJ, DEBENEDETTI CD. Extraintestinal manifestations of chronic inflammatory bowel disease in children. Proc Inst Med Chic 1970; 28: 119.
13. LINDGREN A, WALLERSTEDT S, OLSSON R. Prevalence of Crohn's disease and simultaneous occurrence of extraintestinal complications and cancer. An epidemiologic study in adults. Scand J Gastroenterol 1996; 31: 74-78.
14. ORCHARD TR, THIYAGARAJA S, WELSH KL, WORDSWORTH BP, HILL GASTON JS, JEWELL DP. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000; 118: 274-278.
15. ORCHARD TR, DHAR A, SIMMONS JD, VAUGHAN R, WELSH KI, JEWELL DP. MHC class I chain-like gene A (MICA) and its associations with inflammatory bowel disease and peripheral arthropathy. Clin Exp Immunol 2001; 126: 437-440.
16. VELOSO FT, CARVALHO J, MAGRO F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23: 29-34.
17. MONSÉN U, SORSTAD J, HELLERS G, JOHANSSON C. Extracolonic diagnoses in ulcerative colitis: An epidemiological study. Am J Gastroenterol 1990; 85: 711-716.
18. RUDWALEIT M, BAETEN D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006; 20: 451-471.
19. CIPOLLA G, CREMA F, SACCO S, MORO E, DE PONTI F, FRIGO G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 2002; 46: 1-6.
20. KRUITHOF E, DE RYCKE L, ROTH J, MIELANTS H, VAN DEN BOSCH F, DE KEYSER F, VEYS EM, BAETEN D. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies. Arthritis Rheum 2005; 52: 3898-3909.
21. BARALIAKOS X, DAVIS J, TSUJI W, BRAUN J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52; 1216-1223.
22. GOKHALE R, FAVUS MJ, KARRISON T, SUTTON MM, RICH B, KIRSCHNER BS. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterol 1998; 114: 902-911.
23. SCHOON EJ, BLOK BM, GEERLING BJ, RUSSEL MG, STOCKBRÜGGER RW, BRUMMER RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology 2000; 119: 1203-1208.
24. LOFTUS EV JR, CROWSON CS, SANDBORN WJ, TREMAINE WJ, O'FALLON WM, MELTON LJ 3RD. Long-term fracture risk in patients with Crohn's disease: A population-based study in Olmsted County, Minnesota. Gastroenterology 2002; 123: 468-475.
25. ARDIZZONE S, BOLLANI S, BETTICA P, BEVILACQUA M, MOLTENI P. BIANCHI PORRO G. Altered bone metabolism in inflammatory bowel disease: There is a difference between Crohn's disease and ulcerative colitis. J Intern Med 2000; 247: 63-70.
26. SZUMERA M, LANDOWSKI P, KAMISKA B, GÓRA-GEBKA M, POPADIUK S, RENKE J. Bone mineral density in inflammatory bowel diseases in children. Med Wieku Rozwoj 2006; 10: 445-451.
27. WALTHER F, FUSCH C, RADKE M, BECKERT S, FINDEISEN A. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr 2006; 43: 42-51.
28. CROUCHER PI, VEDI S, MOTLEY RJ, GARRAHAN NJ, STANTON MR, COMPSTON JE. Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporosis Int 1993; 3: 236-241.
29. VESTERGAARD P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med 2004; 95: 469-480.
30. VIDAL NO, BRÄNDSTRÖM H, JONSSON KB, OHLSSON C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: Down-regulation by glucocorticoids. J Endocrinol 1998; 159: 191-195.
31. REDLICH K, HAYER S, MAIER A, DUNSTAN CR, TOHIDAST-AKRAD M, LANG S, TÜRK B, PIETSCHMANN P, WOLOSZCZUK W, HARALAMBOUS S, KOLLIAS G, STEINER G, SMOLEN JS, SCHETT G. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46: 785-792.
32. ROSS PD. Osteoporosis. Frequency, consequences, and risk factors. Arch Intern Med 1996; 156: 1399-1411.
33. BLACK DM, CUMMINGS SR, KARPF DB, CAULEY JA, THOMPSON DE, NEVITT MC, BAUER DC, GENANT HK, HASKELL WL, MARCUS R, OTT SM, TORNER JC, QUANDT SA, REISS TF, ENSRUD KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541.
34. HOFFMANN RM, KRUIS W. Rare extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 140-147.
35. POWELL RJ, HOLBROOK MR, STEVENS A. Pyoderma gangrenosum and its treatment. Lancet 1997; 350: 1720-1721.
36. KUGATHASAN S, MIRANDA A, NOCTON J, DROLET BA, RAASCH C, BINION DG. Dermatologic manifestations of Crohn disease in children: Response to infliximab. J Pediatr Gastroenterol Nutr 2003; 37: 150-154.
37. BARRIE A, PLEVY S. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. Gastroenterol Clin North Am 2006; 35: 883-893.
38. REGUEIRO M, VALENTINE J, PLEVY S, FLEISHER MR, LICHTENSTEIN GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-1826.
39. GUPTA AK, SKINNER AR. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg 2004; 8: 77-89.
40. YU JT, CHONG LY, LEE KC. Metastatic Crohn's disease in a Chinese girl. Hong Kong Med J 2006; 12: 467-469.
41. YTTING H, VIND I, BANG D, MUNKHOLM P. Sweet's syndrome - an extraintestinal manifestation in inflammatory bowel disease. Digestion 2005; 72: 195-200.
42. EL-AZHARY RA, BRUNNER KL, GIBSON LE. Sweet syndrome as a manifestation of azathioprine hypersensitivity. 1: Mayo Clin Proc 2008; 83: 1026-1030.
43. BANET DE, MCCLAVE SA, CALLEN JP. Oral metronidazole, an effective treatment for Sweet's syndrome in a patient with associated inflammatory bowel disease. J Rheumatol 1994; 21: 1766-1768.
44. MINTZ R, FELLER ER, BAHR RL, SHAH SA. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 135-139.
45. RYCHWALSKI PJ, CRUZ OA, ALANIS-LAMBRETON G, FOY TM, KANE RE. Asymptomatic uveitis in young people with inflammatory bowel disease. J AAPOS 1997; 1: 111-114.
46. DIAZ-VALLE D, MIGUELEZ SANCHEZ R, FERNANDEZ ESPARTERO MC, PASCUAL ALLEN D. Treatment of refractory anterior diffuse scleritis with infliximab. Arch Soc Esp Oftalmol 2004; 79: 405-408.
47. FRIES W, GIOFRE MR, CATANOSO M, LO GULLO R. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol 2002; 97: 499-500.
48. TRIPATHI RC, KIRSCHNER BS, KIPP M, TRIPATHI BJ, SLOTWINER D, BORISUTH NS, KARRISON T, ERNEST JT. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology 1992; 102: 1957-1961.
49. STEPHENS M, BATRES LA, NG D, BALDASSANO R. Growth failure in the child with inflammatory bowel disease. Semin Gastrointest Dis 2001; 12: 253-262.
50. KANOF ME, LAKE AM, BAYLESS TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988; 95: 1523-1527.
51. BALLINGER AB, CAMACHO-HÜBNER C, CROFT NM. Growth failure and intestinal inflammation. Q J Med 2001; 94: 121-125.
52. MARX G, SEIDMAN EG, MARTIN SR, DESLANDRES C. Outcome of Crohn's disease diagnosed before two years of age. J Pediatr 2002; 140: 470-473.
53. BALLINGER AB, AZOOZ O, EL-HAJ T, POOLE S, FARTHING MJG. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut 2000; 46: 694-700.
54. FERNANDEZ-BANARES F, CABRE E, ESTEVE-COMAS M, GASSULL MA. How effective is enteral nutrition in inducine clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. J Pediatr Gastroenterology Nutr 1995; 19: 356-364.
55. CALENDA KA, SCHORNAGEL IL, SADEGHI-NEJAD A, GRAND RJ. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: A pilot study. Inflamm Bowel Dis 2005; 11: 435-441.
56. HYAMS J, CRANDALL W, KUGATHASAN S, GRIFFITHS A, OLSON A, JOHANNS J, LIU G, TRAVERS S, HEUSCHKEL R, MARKOWITZ J, COHEN S, WINTER H, VEEREMAN-WAUTERS G, FERRY G, BALDASSANO R; REACH STUDY GROUP. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132: 863-873
57. BALDASSANO R, BRAEGGER CP, ESCHER JC, DEWOODY K, HENDRICKS DF, KEENAN GF, WINTER HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98: 833-838.
58. ANGULO P, LINDOR KD. Primary sclerosing cholangitis. Hepatology 1999; 30: 325-332.
59. BERNSTEIN CN. Extraintestinal manifestations of inflammatory bowel disease. Curr Gastroenterol Rep 2001; 3: 477-483.
60. RASMUSSEN HH, FALLINGBORG J, MORTENSEN PB, FREUND L, TAGE-JENSEN U, KRUSE V, RASMUSSEN SN. Primary sclerosing cholangitis in patients with ulcerative colitis. Scand J Gastroenterol 1992; 27: 732-736.
61. OLSSON R, DANIELSSON A, JARNEROT G, LINDSTRÖM E, LÖÖF L, ROLNY P, RYDÉN BO, TYSK C, WALLERSTEDT S. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100: 1319-1323.
62. DUERR RH, TARGAN SR, LANDERS CJ, LARUSSO NF, LINDSAY KL, WIESNER RH, SHANAHAN F. Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1991; 100: 1385-1391.
63. FELDSTEIN AE, PERRAULT J, EL-YOUSSIF M, LINDOR KD, FREESE DK, ANGULO P. Primary sclerosing cholangitis in children: A long-term follow-up study. Hepatology 2003; 38: 210-217.
64. LIDÉN H, NORRBY J, GÄBEL M, FRIMAN S, OLAUSSON M. Outcome after liver transplantation for primary sclerosing cholangitis. Transplant Proc 2001; 33: 2452-2453.
65. GASCHE C. Complications of inflammatory bowel disease. Hepatogastroenterol 2000; 47: 49-56.
66. WILCOX GM, ARETZ HT, ROY MA, ROCHE JK. Glomerulonephritis associated with inflammatory bowel disease. Report of a patient with chronic ulcerative colitis, sclerosing cholangitis, and acute glomerulonephritis. Gastroenterology 1990; 98: 786-791.
67. LOVAT LB, MADHOO S, PEPYS MB, HAWKINS PN. Long-term survival in systemic amyloid A amyloidosis complicating Crohn's disease. Gastroenterology 1997; 112: 1362-1365.
68. STAWARSKI A, IWANCZAK F. Incidence of acute pancreatitis in children with inflammatory bowel disease. Pol Merkur Lekarski 2004; 17: 33-36.
69. GASCHE C, LOMER MC, CAVILL I, WEISS G. Iron, anemia, and inflammatory bowel disease. Gut 2004; 53: 1190-1197.
70. PARADIS K, BERNSTEIN ML, ADELSON JW. Thrombosis as a complication of inflammatory bowel disease in children: A report of four cases. J Pediatr Gastroenterol Nutr 1985; 4: 659-662.
71. GABAY C, KUSHNER I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
72. FRID C, BJARKE B, ERIKSSON M. Myocarditis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1986; 5: 964-965.
73. PATWARDHAN RV, HEILPERN RJ, BREWSTER AC, DARRAH JJ. Pleuropericarditis: An extraintestinal complication of inflammatory bowel disease. Report of three cases and review of literature. Arch Intern Med 1983; 143: 94-96.
74. AGNHOLT J, SØRENSEN HT, RASMUSSEN SN, GØTZSCHE CO, HALKIER P. Cardiac hypersensitivity to 5-aminosalicylic acid. Lancet 1989; 1: 1135.
75. SEDWICK LA, KUNGELE TG, BURDE RM, BEHRENS MM. Optic neuritis in inflammatory bowel disease. J Clin Neuroophthalmol 1984; 4: 3-6.
76. NEMNI R, FAZIO R, CORBO M, SESSA M, COMI G, CANAL N. Peripheral neuropathy associated with Crohn's disease. Neurology 1987; 37: 1414-1417.
77. AKBAYIR N, CALIS AB, ALKIM C, SÖKMEN HM, ERDEM L, OZBAL A, BÖLÜBA F, AKBAYIR N. Sensorineural hearing loss in patients with inflammatory bowel disease: A subclinical extraintestinal manifestation. Dig Dis Sci 2005; 50: 1938-1945.